Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis (Q40384471)

20 September 2017

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis (English)

1 reference

20 September 2017

1 reference

Mario I Vega

1

1 reference

20 September 2017

Sara Huerta-Yepez

2

1 reference

20 September 2017

Ali R Jazirehi

3

1 reference

20 September 2017

Hermes Garban

4

1 reference

20 September 2017

Benjamin Bonavida

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

20 September 2017

1 reference

20 September 2017

24

1 reference

20 September 2017

55

1 reference

20 September 2017

8114-8127

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1208954

20 September 2017

0 references

cites work

The CD95 type I/type II model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208954

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208954

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference